NEW YORK, Sept. 26, 2017 /PRNewswire/ -- Healthcare technology veteran Carolyn Magill hasbeen appointed CEO of Aetion, a leader in delivering real-world evidence (RWE) and outcomes-based analytics solutions to life science companies and payers. Ms. Magill brings two decades of experience to Aetion, having held executive positions with top
"Achieving the next level of growth requires a leader like Carolyn with experience, vision, and a passion for using technology to transform healthcare," said Jeremy Rassen, co-founder, president and chief scientific officer for Aetion. "Carolyn comes to Aetion with the perspective and know-how to embed the Aetion Evidence Platform™ across the healthcare ecosystem, using its patented rapid-cycle analytics to drive transformative change."
Ms. Magill previously served in senior leadership roles at three of the most important companies driving the transition from fee-for-service to value-based care. As the CEO of Remedy Partners, she led the market-leading company in providing software and services for bundled payment programs. At Evolent Health, Ms. Magill was one of the earliest and most senior executives that led the company from early concept through a successful IPO in 2015, one of the true 'unicorns' created in healthcare. Prior to Evolent, she was UnitedHealth Group's vice president of Medicare Special Needs Plans and COO for UHG's second-largest Medicaid health plan. Ms. Magill earned her bachelor's degree at Harvard University and her M.B.A. in healthcare management from the Wharton School of Business at the University of Pennsylvania.
"After approaching the challenge of paying for value in health care from the payer and provider perspective, it's clear to me that Aetion's technology is the catalyst we need to provide definitive links between clinical decision-making and the quality of patient outcomes," said Ms. Magill. "I'm looking forward to working with such a talented team and incredible platform to provide RWE to constituents across the healthcare ecosystem."
Healthcare decision makers consistently rank better outcomes, actionable evidence and a strong safety profile as their top decision criteria. For the largest payers and innovative life science companies, the Aetion Evidence Platform has repeatedly demonstrated its ability to generate the necessary evidence about outcomes, safety and value in healthcare.
"The healthcare industry is aggressively embracing value," stated Bill Geary, general partner, Flare Capital Partners. "As part of our own market analysis, and echoed by Aetion's customer base, we found the company's solution to be the clear leader in delivering the science and analytics needed to power outcomes-based contracting. We are pleased to be working with our co-investors at Lakestar and Oxeon Ventures -- who made Aetion their inaugural investment in their new fund -- to help build the market-leading company."
Based in New York City, Aetion (pronounced eh-tee-ahn) is a leading healthcare technology company that delivers the real-world analytics and evidence needed for value-based care. With its patented rapid-cycle analytics™ technology, the Aetion Evidence Platform utilizes the everyday clinical and financial interactions of the healthcare system to unlock essential evidence about the effectiveness and value of medical treatments. Founded by Harvard Medical School faculty members and top big data technologists, Aetion enables payers and providers to collaborate with biopharmaceutical and medical device companies in real-time to develop therapeutic insights and make smart choices in patient care. The company is backed by Flare Capital Partners, Lakestar, Oxeon Ventures and other leading individual health technology investors. Learn more at www.aetion.com.
Media Contact:Jack Haanraadts for AetionFinn Partnersaetionteam@finnpartners.com +1 212.715.1695
View original content:http://www.prnewswire.com/news-releases/aetion-accelerates-growth-strategy-appointing-carolyn-magill-as-chief-executive-officer-300525233.html
Subscribe to our Free Newsletters!
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...View All